Related Experiment Video
Updated: May 15, 2025

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
AI drug development's data problem
E Richard Gold1, Robert Cook-Deegan2
1E. Richard Gold is at the Faculty of Law and Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada; is Chief Policy and Partnerships Officer, Conscience, Toronto, ON, Canada; and is senior fellow, Centre for International Governance Innovation, Waterloo, ON, Canada.
Abstract:
The future of drug discovery may be artificial intelligence (AI), but its present is not. AI is in its infancy in the field. To help AI mature, developers need nonproprietary, open, large, high-quality datasets to train and validate models, managed by independent organizations.
Related Concept Videos
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Preclinical Development: Overview
Clinical Trials: Overview
Drug Regulation

